Denise Bronner, Ph.D., makes the case for and against acquisitions for rejuvenating Big Pharma pipelines. She explains why ...

Swiss Roche, U.S. Merck (MSD), and Japan's Takeda have also ... MSD attracted attention by acquiring U.S. biotech company Prometheus Bioscience for $10.8 billion (approximately 15 trillion won ...

Merck’s $10.8 billion acquisition of Prometheus Biosciences and Roche’s $7.1 billion deal to acquire Televant underscore the high stakes in this therapeutic area. Piper Sandler analyst ...

MSD – known as Merck & Co in North America – acquired rights to PRA023 (now MK-7240) when it bought Prometheus Biosciences for $10.8 billion earlier this year, while Roche was recently ...

But Teva and Sanofi are far from alone in their efforts. Also last year, Merck spent $10.8 billion to acquire Prometheus Biosciences for its experimental TL1A drug. Roche paid $7.1 billion to take ...

MSD, known as Merck & Co in the US and Canada ... notably buying Acceleron for $11.5 billion in 2021 and Prometheus for $10.8 billion a year later, along with several smaller-scale deals.

Correspondence to Professor Rohit Loomba, Department of Medicine, University of California San Diego, La Jolla CA 92037, USA; roloomba{at}ucsd.edu Objective Emerging data suggest that a 30% relative ...

Merck's stock trades at a low valuation as investors worry about Keytruda's looming patent cliff. The company is looking to a new, subcutaneous formulation, which could help sales remain strong ...

Merck MRK announced that it has entered into an exclusive licensing deal with China-based Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma) for the latter’s investigational oral small-molecule ...

(Bloomberg) -- Merck & Co. will pay as much as $2 billion for the rights to Jiangsu Hengrui Pharmaceuticals Co.’s experimental heart drug, the US drugmaker’s second recent foray into China for ...